Delivery Order SPE2DB22D1200-SPE2DB25FN4PM
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $31,396.02. This firm fixed price delivery order, which represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX, valued at $999,999,999.00 through December 2026), was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Creon DR 36,000 unit capsules in units of 100, with a contract ceiling value of $2,335.13 and an ultimate completion date of July 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for 36,000 units of Creon DR 100s capsules with a ceiling value of $5,071.22. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 24, 2025. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $9,164.04. This competitively awarded, firm fixed-price delivery order, with no set-aside designation, is scheduled for completion by September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Creon DR 24,000 unit capsules (100 count) with a ceiling value of $2,262.52 and an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of 24,000 units of Creon DR 100s capsules, with a contract ceiling value of $7,467.22. This is a firm fixed-price delivery order with an ultimate completion date of September 5, 2025, and represents a non-set-aside, competitively awarded contract. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of 36,000 units of Creon DR capsules (100s formulation) with a ceiling value of $7,070.70. This firm fixed-price delivery order is not set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 15, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania,...
- The Defense Logistics Agency awarded a $14,406.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for 36,000 unit capsules of Creon (pancrelipase) in 100-count packages, with completion scheduled for September 10, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award is non-set-aside and was...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $59,616.66 to AmerisourceBergen Drug Corp for the supply of Creon DR 36,000 Unit Capsules in quantities of 100s. This firm fixed-price delivery order, issued on September 8, 2025, represents a non-set-aside competitive award with an ultimate completion date of September 9, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of 24,000 unit capsules of Creon DR 100s, with a ceiling value of $8,755.73 and a firm fixed price structure. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order is scheduled for completion by August...
- SPE2DB22D1200Indefinite Delivery Contract
- SPE2DB22D1200-SPE2DB25FN4PMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of 36,000 unit capsules of Creon DR 100s with a ceiling value of $58,274.04. This firm fixed-price delivery order is scheduled for completion by September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation and represents a continuation of the company's role as a critical pharmaceutical supplier to the Department of Defense medical supply chain. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a prime vendor under this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies a broad range of medications and medical supplies to support military healthcare programs and other federal customers, including the Defense Health Agency and U.S. Coast Guard. The supply of Creon DR—a pancreatic enzyme replacement therapy—supports military healthcare operations and demonstrates the company's continued capability to fulfill specialized pharmaceutical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $58.3k | 9/23/25 |